2,501
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

The anti-obesity effects of Lactobacillus casei strain Shirota versus Orlistat on high fat diet-induced obese rats

, , , , , , & show all
Article: 29273 | Received 26 Jul 2015, Accepted 26 Nov 2015, Published online: 22 Dec 2015

References

  • An HM, Lee DK, Kim JR, Cha MK, Lee SW, Lim HT, etal. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis. 2011; 10: 116.
  • World Health Organization. Obesity and overweight. 2015. Fact sheet N°. 311, Media Centre. [Updated January 2015]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ cited 12 February 2015]..
  • Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, etal. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010; 362: 590–9.
  • Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association of Predictive, Preventive and Personalised Medicine. EPMA J. 2012; 3: 1–53.
  • Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Ann Rev Med. 2013; 64: 45–57.
  • Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried W, etal. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res. 2012; 5: 1260–72.
  • Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012; 53: 100–8.
  • Kang J-H, Yun S-I, Park M-H, Park J-H, Jeong S-Y, Park H-O. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One. 2013; 8: e54617.
  • Hamad EM, Sato M, Uzu K, Yoshida T, Higashi S, Kawakami H, etal. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br J Nutr. 2009; 101: 716–24.
  • Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007; 104: 979–84.
  • Karimi G, Jamaluddin R, Parvaneh K. The effects of probiotics on body weight and biomarkers of animal. Pakistan J Nutr. 2013; 12: 793–9.
  • Zhang Y-J, Li S, Gan R-Y, Zhou T, Xu D-P, Li H-B. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015; 16: 7493–519.
  • Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2013; 5: 3–17.
  • Leung J, Burke B, Ford D, Garvin G, Korn C, Sulis C, etal. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis. 2013; 19: 1791.
  • Tanida M, Shen J, Maeda K, Horii Y, Yamano T, Fukushima Y, etal. High-fat diet-induced obesity is attenuated by probiotic strain Lactobacillus paracasei ST11 (NCC2461) in rats. Obes Res Clin Pract. 2008; 2: 159–69.
  • Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, etal. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet - induced obesity mice. J Appl Microbiol. 2011; 110: 650–7.
  • Matsumoto K, Takada T, Shimizu K, Moriyama K, Kawakami K, Hirano K, etal. Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. J Biosci Bioeng. 2010; 110: 547–52.
  • Matsuzaki T.Edward RF. Health properties of milk fermented with Lactobacillus casei strain Shirota (LcS). Handbook of fermented functional foods. 2003; Boca Raton, FL: CRC Press. 165–72. 2ed ed..
  • Díaz EG, Folgueras TM. Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents. Nutr Hosp. 2011; 26: 451–7.
  • Núñez IN, Galdeano CM, de Moreno de LeBlanc A, Perdigón G. Lactobacillus casei CRL 431 administration decreases inflammatory cytokines in a diet induced obese mouse model. Nutrition. 2015; 31: 1000–7.
  • Firouzi S, Barakatun-Nisak MY, Ismail A, Majid HA, Azmi KN. Role of probiotics in modulating glucose homeostasis: evidence from animal and human studies. Int J Food Sci Nutr. 2013; 64: 780–6.
  • Wu C-C, Weng W-L, Lai W-L, Tsai H-P, Liu W-H, Lee M-H, etal. Effect of Lactobacillus plantarum strain K21 on high-fat diet-fed obese mice. Evid Based Complement Alternat Med. 2015; 2015: 391767.
  • Yoda K, Sun X, Kawase M, Kubota A, Miyazawa K, Harata G, etal. A combination of probiotics and whey proteins enhances anti-obesity effects of calcium and dairy products during nutritional energy restriction in aP2-agouti transgenic mice. Br J Nutr. 2015; 113: 1689–96.
  • Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012; 108: 459–70.
  • López P, Gueimonde M, Margolles A, Suárez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010; 138: 157–65.
  • Parvaneh K, Jamaluddin R, Karimi G, Erfani R. Effect of probiotics supplementation on bone mineral content and bone mass density. Scientific World Journal. 2014; 2014: 595962.
  • Stenman L, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes. 2014; 5: 437–45.
  • Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009; 9: 737–43.
  • Oelschlaeger TA. Mechanisms of probiotic actions – a review. Int J Med Microbiol. 2010; 300: 57–62.
  • Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, etal. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334: 292–5.
  • Lee H-Y, Park J-H, Seok S-H, Baek M-W, Kim D-J, Lee K-E, etal. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006; 1761: 736–44.
  • Ahima RS, Flier JS. Leptin. Ann Rev Physiol. 2000; 62: 413–37.
  • Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372: 425–32.
  • Sato M, Uzu K, Yoshida T, Hamad EM, Kawakami H, Matsuyama H, etal. Effects of milk fermented by Lactobacillus gasseri SBT2055 on adipocyte size in rats. Br J Nutr. 2008; 99: 1013–17.
  • Whitehead J, Richards A, Hickman I, Macdonald G, Prins J. Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006; 8: 264–80.
  • Gao X-L, Yang H-X, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J. 2008; 121: 701–5.
  • Feng W, Yuan X, Tong G, Wang W, Hu Y, Shen S, etal. Correlated increase of omentin-and adiponectin by exenatide, avandamet, and dietary change in diet-induced obese rats. Folia Biol (Praha). 2013; 59: 217–24.
  • Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, etal. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010; 64: 636–43.
  • Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counseling during pregnancy on colostrum adiponectin concentration: a prospective, randomized, placebo-controlled study. Early Hum Dev. 2012; 88: 339–44.
  • Nerstedt A, Nilsson EC, Ohlson K, Håkansson J, Thomas Svensson L, Löwenadler B, etal. Administration of Lactobacillus evokes coordinated changes in the intestinal expression profile of genes regulating energy homeostasis and immune phenotype in mice. Br J Nutr. 2007; 97: 1117–27.
  • Hulston CJ, Churnside AA, Venables MC. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br J Nutr. 2015; 113: 596–602.
  • Das UN. Is metabolic syndrome X an inflammatory condition?. Exp Biol Med. 2002; 227: 989–97.
  • Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003; 168: 351–8.
  • Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, etal. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006; 17: 4–12.
  • Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol. 2009; 44: 26–46.
  • Andreasen AS, Sofie A, Larsen N, Pedersen-Skovsgaard T, Berg RM, Møller K, etal. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010; 104: 1831–8.
  • Gøbel RJ, Larsen N, Jakobsen M, Mølgaard C, Michaelsen KF. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr. 2012; 55: 673–8.
  • Park YH, Kim JG, Shin YW, Kim HS, Kim Y-J, Chun T, etal. Effects of Lactobacillus acidophilus 43121 and a mixture of Lactobacillus casei and Bifidobacterium longum on the serum cholesterol level and fecal sterol excretion in hypercholesterolemia-induced pigs. Biosci Biotechnol Biochem. 2008; 72: 595–600.
  • Xiao J, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, etal. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci. 2003; 86: 2452–61.
  • Dicker D, Herskovitz P, Katz M, Atar E, Bachar GN. Computed tomography study of the effect of orlistat on visceral adipose tissue volume in obese subjects. Israel Med Assoc J. 2010; 12: 199–202.
  • Blackburn GL, Waltman BA. Pharmacotherapy to reduce visceral fat. Clin Cornerstone. 2005; 7: 52–60.